Breast Cancer

A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.

In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.

The combo showed improvement in disease-free survival over tamoxifen in premenopausal patients with hormone receptor (HR)-positive early breast cancer.

In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.

In this video, Dr. Nancy Davidson highlights current and next-generation diagnostics and therapies in breast cancer, as well as the need for “team science” in clinical trials.

Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.

The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2− breast cancer patients.

Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.

A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.

Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.

Researchers tested whether combining chemotherapy with immunotherapy would offer improved survival for patients with triple-negative breast cancer.

In this study, researchers evaluated changes in CVD risk factors and 10-year CVD risk from before to after a breast cancer diagnosis, and compared it with women who remained free of such a diagnosis.

While becoming pregnant is generally possible for younger breast cancer patients, researchers believe many women change their minds after treatment.

In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy.

This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.

An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?

Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making.

In a first-of-its-kind study, researchers analyzed how Twitter users talk about breast cancer on the social media platform.

We take a look at how a healthy diet can improve quality of life in breast cancer survivors.

A novel cancer vaccine targeting HER2-positive malignancies has progressed quickly from mouse trials into early-phase human trials, with promising results.

Different cytotoxic chemotherapy regimens are associated with varying rates of hospitalization following their use in older women with stage IV breast cancer.

The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer.

Nearly 10 years of follow-up from a large clinical trial have confirmed that axillary dissection is not necessary in patients with early breast cancer.

Survival has increased substantially for young women with breast cancer since 1975, though it has largely reached a plateau since around 2005.

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches.